Lite Strategy, Inc. (LITS)
Last updated: 2026-10-23 22:23:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Lite Strategy, Inc. (LITS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.17, with a market capitalization of $37.71M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.69 to $2.26. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$37.71M | |
$1.19 | |
$3.23 | |
$0.69 | |
$1.19 | |
138.08K | |
483.00K | |
-- | |
$2.26 | |
$0.69 | |
-- | |
-- |
Lite Strategy, Inc. (LITS) After-Hours Stock Price
Lite Strategy, Inc. (LITS) is trading at $1.17 in after-hours trading as of 2026-10-23 20:11:00, down 2.10% ($0.02) from the regular-session close of $1.19.
After-hours trading shows how investors are pricing LITS after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Lite Strategy, Inc. (LITS) 7-Day Stock Price Change
Over the past seven days, Lite Strategy, Inc. (LITS) moved from $1.17 to $1.17, representing a decline of 0.43% ($0.00).
The stock traded between $1.13 and $1.31 during the period. The latest price is near the lower end of the 7-day range, indicating range-bound.
The average daily volume was 209.36 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
LITS 52-Week Price Position
Position in Range: 30.3%
LITS is currently trading at $1.17, placing it 30.3% of the way from its 52-week low of $0.69 to its 52-week high of $2.26. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Lite Strategy, Inc. (LITS)?
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.
Lite Strategy, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Lite Strategy, Inc. (LITS) Stock on MEXC
Eligible investors can buy real shares of Lite Strategy, Inc. (LITS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Lite Strategy, Inc. (LITS) stock price today?
2.Is LITS stock going up or down today?
3.What is LITS pre-market price?
4.What is LITS after-hours price?
5.Is LITS stock trading now?
6.Where does LITS sit relative to its 52-week high and low?
7.What sector is Lite Strategy, Inc. in?
8.What is Lite Strategy, Inc.'s market capitalization and where is it listed?
9.How is LITS valued in terms of P/E ratio and EPS?
10.Does Lite Strategy, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
LITS Stock Calculator
Estimate the value between LITS shares and USD.
LITS Shares to USD
1.00 LITS shares = 1.165 USD
Calculations are estimates based on the latest available price and are for reference only.


